Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Neuropathy - Drugs In Development, 2022, provides an overview of the Diabetic Neuropathy (Metabolic Disorders) pipeline landscape.
Diabetic neuropathy, a common complication of diabetes, is damage to the nerves that allow feeling things such as pain. Symptoms include tingling, numbness, burning and pain. The predisposing factors are obesity, hypertension, high lipid and sugar levels, smoking, etc. It may be managed by medication and dietary modification.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diabetic Neuropathy - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Diabetic Neuropathy (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Diabetic Neuropathy (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Neuropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 8, 7, 18 and 6 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Diabetic Neuropathy (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Neuropathy (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Diabetic Neuropathy (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Diabetic Neuropathy (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Diabetic Neuropathy (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Neuropathy (Metabolic Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Diabetic Neuropathy (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Diabetic Neuropathy (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
'
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Diabetic Neuropathy - Overview
Diabetic Neuropathy - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Diabetic Neuropathy - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Diabetic Neuropathy - Companies Involved in Therapeutics Development
Achelios Therapeutics Inc
Applied Therapeutics Inc
Beijing Tide Pharmaceutical Co Ltd
Bexion Pharmaceuticals LLC
Celon Pharma SA
CSPC Pharmaceutical Group Ltd
Epigen Biosciences Inc
Exodos Life Sciences Limited Partnership
Frontbio Co Ltd
G&P Bioscience Co Ltd
Glycadia Inc
Grunenthal GmbH
Han Wha Pharma Co Ltd
Ion Channel Pharmacology LLC
JanOne Inc
Korea United Pharm Inc
Medifron DBT Co Ltd
Mitsubishi Tanabe Pharma Corp
Omeros Corp
Ono Pharmaceutical Co Ltd
Palisade Bio, Inc
Praetego Inc
Pure Green Pharmaceuticals Inc
Reata Pharmaceuticals Inc
Releviate Therapeutics
Shandong Huizhi Pharmaceutical Technology Co Ltd
Sichuan Haisco Pharmaceutical Co Ltd
Sonnet BioTherapeutics Holdings Inc
WEX Pharmaceuticals Inc
Winsantor Inc
Zelira Therapeutics Ltd
Zhejiang Pharmaceutical Co Ltd
Diabetic Neuropathy - Drug Profiles
A-717 - Drug Profile
Product Description
Mechanism Of Action
atexakin alfa - Drug Profile
Product Description
Mechanism Of Action
BXQ-350 - Drug Profile
Product Description
Mechanism Of Action
caficrestat - Drug Profile
Product Description
Mechanism Of Action
CPL-207280CA - Drug Profile
Product Description
Mechanism Of Action
elismetrep - Drug Profile
Product Description
Mechanism Of Action
EPGN-2154 - Drug Profile
Product Description
Mechanism Of Action
FB-118B1 - Drug Profile
Product Description
Mechanism Of Action
GB-102 - Drug Profile
Product Description
Mechanism Of Action
GLY-230 - Drug Profile
Product Description
Mechanism Of Action
HSK-16149 - Drug Profile
Product Description
Mechanism Of Action
ketoprofen - Drug Profile
Product Description
Mechanism Of Action
KU-32 - Drug Profile
Product Description
Mechanism Of Action
lidocaine - Drug Profile
Product Description
Mechanism Of Action
MDR-16523 - Drug Profile
Product Description
Mechanism Of Action
MDR-652 - Drug Profile
Product Description
Mechanism Of Action
Monoclonal Antibodies to Inhibit MASP-2 for Diabetic Complications and Rheumatoid Arthritis - Drug Profile
Product Description
Mechanism Of Action
NSI-189 - Drug Profile
Product Description
Mechanism Of Action
ONO-2910 - Drug Profile
Product Description
Mechanism Of Action
Peptide to Activate G Protein-Coupled Receptor Mas for Cardiovascular, Metabolic Disorders and Male Health - Drug Profile
Product Description
Mechanism Of Action
PGDN-20WS - Drug Profile
Product Description
Mechanism Of Action
pirenzepine - Drug Profile
Product Description
Mechanism Of Action
PTG-6 - Drug Profile
Product Description
Mechanism Of Action
PTG-640 - Drug Profile
Product Description
Mechanism Of Action
PTG-641 - Drug Profile
Product Description
Mechanism Of Action
resiniferatoxin - Drug Profile
Product Description
Mechanism Of Action
RLVT-1402 - Drug Profile
Product Description
Mechanism Of Action
RLVT-903 - Drug Profile
Product Description
Mechanism Of Action
RTA-901 - Drug Profile
Product Description
Mechanism Of Action
Small Molecule for Algodystrophy, Chemotherapy Induced Peripheral Neuropathy, Diabetic Peripheral Neuropathy and Pain - Drug Profile
Product Description
Mechanism Of Action
Small Molecule for Diabetic Peripheral Neuropathy - Drug Profile
Product Description
Mechanism Of Action
Small Molecule to Agonize MOR1 for Chemotherapy Induced Peripheral Neuropathy, Diabetic Peripheral Neuropathy and Postherpetic Neuralgia - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Agonize CB1 and CB2 for Diabetic Neuropathy and Peripheral Arterial Disease - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Target Plasminogen for Chronic Inflammatory Diseases and Diabetic Neuropathy - Drug Profile
Product Description
Mechanism Of Action
sodium nitrite SR - Drug Profile
Product Description
Mechanism Of Action
SYHA-1402 - Drug Profile
Product Description
Mechanism Of Action
Tetrodotoxin - Drug Profile
Product Description
Mechanism Of Action
UI-016 - Drug Profile
Product Description
Mechanism Of Action
UI-048 - Drug Profile
Product Description
Mechanism Of Action
YJ-001 - Drug Profile
Product Description
Mechanism Of Action
YJC-007 - Drug Profile
Product Description
Mechanism Of Action
Diabetic Neuropathy - Dormant Projects
Diabetic Neuropathy - Discontinued Products
Diabetic Neuropathy - Product Development Milestones
Featured News & Press Releases
Aug 02, 2021: Innovative drug HSK16149 capsule was approved to carry out phase II clinical trial of "auxiliary opioid analgesia"
Jun 02, 2021: Innovative drug HSK16149 capsule new indications obtained IND application "Notice of Acceptance"
May 13, 2021: Pure Green Pharmaceuticals reports unexpected results of a randomized, placebo controlled clinical trial with sublingual CBD in patients with painful diabetic peripheral neuropathy
Apr 01, 2021: Celon Pharma announces CPL’280, second generation oral GPR40 agonist, meets primary endpoint in phase 1 trial
Jan 25, 2021: Sonnet BioTherapeutics announces the successful completion of a non-human primate toxicology study of SON-080
Sep 30, 2020: Praetego receives NIH phase 2 STTR funding to advance novel amadorin drug candidates for diabetic peripheral neuropathy
Apr 12, 2019: “SYHA1402” for the treatment of diabetic neuropathy was granted clinical trial approval
Jun 01, 2018: Reata Selected to Present on its Early-Stage Program RTA 901 at the BIO International Convention
Mar 16, 2018: Reata to Present on its Diabetic Neuropathy Drug Candidate RTA-901 at the BIO Asia International Conference
Aug 02, 2017: Neuralstem Awarded $~1MM Grant by NIH to Continue Preclinical Research into the Potential of NSI-189 for Treatment of Diabetic Neuropathy
Sep 04, 2016: Salvianolic acid A tablets developed by the National Drug Screening Center received clinical approval
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Diabetic Neuropathy, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Diabetic Neuropathy - Dormant Projects, 2022
Diabetic Neuropathy - Dormant Projects, 2022 (Contd..1)
Diabetic Neuropathy - Dormant Projects, 2022 (Contd..2)
Diabetic Neuropathy - Dormant Projects, 2022 (Contd..3)
Diabetic Neuropathy - Discontinued Products, 2022
List of Figures
Number of Products under Development for Diabetic Neuropathy, 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022
